Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Multivitamin use doesn't impact colon cancer outcomes

08.09.2010
Patients with colon cancer who used multivitamins during and after being treated with post-surgical chemotherapy did not reduce the risk of the cancer returning or their dying from it, according to researchers at Dana-Farber Cancer Institute.

In a study of patients with stage III colon cancer – characterized as cancer in the large bowel area with some cancer cells in a few nearby lymph nodes -- the researchers found that while multivitamin use had no beneficial effect on patients' outcomes, it also did not have a detrimental effect. The findings are reported online in the Journal of Clinical Oncology and later will be published in a print edition.

Kimmie Ng, MD, MPH, the paper's first author and a gastrointestinal oncologist at Dana-Farber, said that despite conflicting evidence on the efficacy of multivitamins to reduce cancer risk and death, studies suggest that approximately 30 percent of Americans take multivitamins to prevent and treat chronic diseases such as cancer. Among cancer survivors, between 26 and 77 percent report using multivitamins.

"With such a high proportion of cancer patients utilizing multivitamin supplements in the belief that it will help them fight their cancer, we felt it was important to really examine the data to see what impact multivitamins had on cancer recurrence and survival," said Ng.

The researchers used two questionnaires to track multivitamin use during and after chemotherapy. Of the 1,038 patients who completed the first survey, nearly half (518) responded they used multivitamins while receiving chemotherapy. Of the 810 cancer-free patients who completed the second survey six months after chemotherapy, more than half (416) reported multivitamin use.

Ng and her colleagues found no statistically significant differences in the rates of disease-free survival (the study's primary endpoint), recurrence-free survival, or overall survival between those who used multivitamins and those who didn't.

They also determined that an array of factors, including socio-economic status, household income, multivitamin and individual vitamin dosage, and consistency of multivitamin use did not impact their findings.

However, they did find a small beneficial association between age and weight and the use of multivitamins while receiving chemotherapy. Those 60 and younger experienced some survival benefit, as did obese patients. There were no benefits for either subgroup when the multivitamins were taken after chemotherapy was completed. Ng said additional studies are needed to confirm their findings and to investigate whether there were other factors that influenced the outcomes.

"This study adds to a growing body of research that questions the purported benefit of multivitamin use, and it underscores the need to investigate the use of individual vitamins, such as vitamin D, which may, in fact, provide real benefit," said Charles Fuchs, MD, director of gastrointestinal oncology at Dana-Farber and the paper's senior author. He noted that the average multivitamin typically contains only a small to modest amount of vitamin D.

The study was funded in part by the National Cancer Institute and by an American Society of Clinical Oncology Young Investigator Award.

In addition to Ng and Fuchs, the other authors are Jeffrey A. Meyerhardt, MD, MPH, Jennifer Chan, MD, and Robert J. Mayer, MD, Dana-Farber; Donna Niedzwiecki, PhD, and Donna R. Hollis, BS, Duke University; Leonard Saltz, MD, Memorial Sloane Kettering Cancer Center; Al B. Benson, III, MD, Lurie Comprehensive Cancer Center, Chicago; Paul L. Schaefer, MD, Toledo Community Hospital Oncology Program, Toledo, OH; Renaud Whittom, MD, Hôpital du Sácre-Coeur de Montréal; Alexander Hantel, MD, Edward Cancer Center, Naperville, IL; and Richard M. Goldberg, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, N.C.

Dana-Farber Cancer Institute (www.dana-farber.org) is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute. It provides adult cancer care with Brigham and Women's Hospital as Dana-Farber/Brigham and Women's Cancer Center and it provides pediatric care with Children's Hospital Boston as Dana-Farber/Children's Hospital Cancer Center. Dana-Farber is the top ranked cancer center in New England, according to U.S. News & World Report, and one of the largest recipients among independent hospitals of National Cancer Institute and National Institutes of Health grant funding.

Bill Schaller | EurekAlert!
Further information:
http://www.dana-farber.org

Further reports about: Cancer Dana-Farber MPH Multivitamin chronic disease lymph node

More articles from Health and Medicine:

nachricht Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center

nachricht Study advances gene therapy for glaucoma
17.01.2018 | University of Wisconsin-Madison

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

Im Focus: A thermometer for the oceans

Measurement of noble gases in Antarctic ice cores

The oceans are the largest global heat reservoir. As a result of man-made global warming, the temperature in the global climate system increases; around 90% of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

World’s oldest known oxygen oasis discovered

18.01.2018 | Earth Sciences

Uncovering decades of questionable investments

18.01.2018 | Business and Finance

Novel chip-based gene expression tool analyzes RNA quickly and accurately

18.01.2018 | Medical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>